NCT00167310View on ClinicalTrials.gov

Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation

PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
SchizophreniaSchizoaffective DisorderMajor DepressionBipolar DisorderCoronary Artery Disease
Interventions
DRUG

Eicosapentaenoic acid (omega-3 fatty acid)

2 g of Eicosapentaenoic acid in 4 x 500 mg capsules daily for baseline, 1 month, 2 months and 4 months

DRUG

Placebo

2 g of Placebo (soy bean oil) in 4 x 500 mg capsules daily for baseline, 1 month, 2 months and 4 months

Trial Locations (1)

15240

VA Pittsburgh Healthcare System (University Drive), Pittsburgh

All Listed Sponsors
collaborator

American Heart Association

OTHER

collaborator

VA Pittsburgh Healthcare System

FED

lead

University of Pittsburgh

OTHER

NCT00167310 - Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation | Biotech Hunter | Biotech Hunter